Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Edit custom filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2007 1
2008 1
2009 1
2012 2
2013 2
2014 8
2015 4
2016 4
2017 5
2018 5
2019 8
2020 28
2021 18
2022 17
2023 12
2024 14
2025 10
2026 10

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

136 results

Results by year

Filters applied: . Clear all
Page 1
Neoadjuvant Chemotherapy With Oxaliplatin and Fluoropyrimidine Versus Upfront Surgery for Locally Advanced Colon Cancer: The Randomized, Phase III OPTICAL Trial.
Hu H, Zhang J, Li Y, Wang X, Wang Z, Wang H, Kang L, Liu P, Lan P, Wu X, Zhen Y, Pei H, Huang Z, Zhang H, Chen W, Zeng Y, Lai J, Wei H, Huang X, Chen J, Chen J, Tao K, Xu Q, Peng X, Liang J, Cai G, Ding K, Ding Z, Hu M, Zhang W, Tang B, Hong C, Cao J, Huang Z, Cao W, Li F, Wang X, Wang C, Huang Y, Zhao Y, Cai Y, Ling J, Xie X, Wu Z, Shi L, Ling L, Liu H, Wang J, Huang M, Deng Y; OPTICAL study group. Hu H, et al. J Clin Oncol. 2024 Sep 1;42(25):2978-2988. doi: 10.1200/JCO.23.01889. Epub 2024 Apr 2. J Clin Oncol. 2024. PMID: 38564700 Clinical Trial.
Neoadjuvant PD-1 blockade with toripalimab, with or without celecoxib, in mismatch repair-deficient or microsatellite instability-high, locally advanced, colorectal cancer (PICC): a single-centre, parallel-group, non-comparative, randomised, phase 2 trial.
Hu H, Kang L, Zhang J, Wu Z, Wang H, Huang M, Lan P, Wu X, Wang C, Cao W, Hu J, Huang Y, Huang L, Wang H, Shi L, Cai Y, Shen C, Ling J, Xie X, Cai Y, He X, Dou R, Zhou J, Ma T, Zhang X, Luo S, Deng W, Ling L, Liu H, Deng Y. Hu H, et al. Lancet Gastroenterol Hepatol. 2022 Jan;7(1):38-48. doi: 10.1016/S2468-1253(21)00348-4. Epub 2021 Oct 22. Lancet Gastroenterol Hepatol. 2022. PMID: 34688374 Clinical Trial.
Evolving Concept of Activity Cliffs.
Stumpfe D, Hu H, Bajorath J. Stumpfe D, et al. Among authors: hu h. ACS Omega. 2019 Aug 26;4(11):14360-14368. doi: 10.1021/acsomega.9b02221. eCollection 2019 Sep 10. ACS Omega. 2019. PMID: 31528788 Free PMC article. Review.
TRIBE2 results and toxicity.
Zhang J, Cai Y, Xie X, Hu H, Deng Y. Zhang J, et al. Among authors: hu h. Lancet Oncol. 2020 Jun;21(6):e298. doi: 10.1016/S1470-2045(20)30270-9. Lancet Oncol. 2020. PMID: 32502450 No abstract available.
Reply to Y.-Y. Qiu et al.
Hu H, Zhang J, Shi L, Huang M, Wang J, Deng Y. Hu H, et al. J Clin Oncol. 2024 Oct 10;42(29):3510-3511. doi: 10.1200/JCO-24-01217. Epub 2024 Jul 24. J Clin Oncol. 2024. PMID: 39047220 No abstract available.
Neoadjuvant toripalimab plus celecoxib versus toripalimab monotherapy for mismatch repair-deficient or microsatellite instability-high, locally advanced colorectal cancer (PICC-2): an open-label, multicentre, randomised, phase 2 trial.
Hu H, Shen X, Li Y, Zhou J, Liu P, Zhang J, Hou Y, Wang X, Deng J, Zheng Z, Li J, Lan P, Wu X, Kang L, Huang M, He Z, He X, Yang Z, Huang L, Wang H, Wang H, Luo S, Chen D, Xie X, Zhang Y, Zhai X, Li S, Li W, Hu J, Yang T, Wang C, Deng W, Huang Y, Cao W, Li F, Shi L, Ling L, Deng Y. Hu H, et al. Lancet Oncol. 2026 Aug;27(8):1020-1030. doi: 10.1016/S1470-2045(26)00220-2. Epub 2026 Jul 1. Lancet Oncol. 2026. PMID: 42385761
Neoadjuvant PD-1 blockade with toripalimab with or without celecoxib for patients with mismatch repair-deficient or microsatellite instability-high, locally advanced, colorectal cancer (PICC): long-term outcomes of a single-centre, parallel-group, non-comparative, randomised phase 2 trial.
Shen X, Cai Y, Li W, Shi L, Zhang J, Xie X, Wu Z, Zheng Z, Cao W, Deng Y, Hu H. Shen X, et al. Among authors: hu h. EClinicalMedicine. 2025 Sep 12;88:103499. doi: 10.1016/j.eclinm.2025.103499. eCollection 2025 Oct. EClinicalMedicine. 2025. PMID: 41181826 Free PMC article.
136 results